Senolytics Target a Hidden Molecular Complex to Reverse Vascular Cell Aging
Dasatinib and quercetin combat blood vessel aging by breaking up a newly discovered RNA-protein complex that drives inflammatory senescence.
Summary
Researchers identified a novel mechanism by which the senolytic combination dasatinib and quercetin (D+Q) combats vascular aging. A long non-coding RNA called JPX was found to form a complex with proteins BRD4 and p65 in endothelial cells, amplifying the senescence-associated secretory phenotype (SASP) — a harmful inflammatory state linked to aging diseases. Using LPS-induced senescent human umbilical vein endothelial cells, the team showed that JPX levels rise during senescence and that suppressing JPX reduces cellular aging markers, while increasing JPX worsens them. Senolytics disrupted the JPX-BRD4-p65 complex both in lab models and in vivo, effectively reducing endothelial senescence. This work uncovers JPX as a key driver of vascular endothelial aging and suggests the JPX-BRD4-p65 axis as a therapeutic target.
Detailed Summary
Vascular aging is a root cause of cardiovascular disease, and senescence of the endothelial cells lining blood vessels plays a central role. Understanding what drives this senescence — and how drugs might reverse it — is a priority in longevity medicine. This study sheds important new light on both questions.
Researchers focused on JPX, a long non-coding RNA previously linked to smooth muscle cell senescence, but whose role in endothelial cells (ECs) was unknown. Using human umbilical vein endothelial cells (HUVECs) treated with lipopolysaccharide (LPS) to induce senescence, they found JPX expression rose significantly in senescent cells. Manipulating JPX levels confirmed its causal role: knockdown reduced senescence markers, while overexpression worsened them.
Mechanistically, JPX was found to physically interact with BRD4 (a bromodomain epigenetic reader protein) and the transcription factor p65 (a key NF-κB subunit), forming a trimolecular JPX-BRD4-p65 complex. This complex promoted transcription of SASP genes — the inflammatory secretome that makes senescent cells harmful to surrounding tissue and systemic health.
Critically, the senolytic combination dasatinib and quercetin disrupted this complex both in cell culture and in vivo models, reducing SASP expression and alleviating endothelial senescence. This provides a molecular explanation for how D+Q exerts anti-aging effects in the vasculature beyond simply clearing senescent cells.
Caveats include reliance on an LPS-induced senescence model, which may not fully replicate the complexity of age-related vascular senescence. The study also lacks direct human aging tissue validation. Nonetheless, identifying the JPX-BRD4-p65 axis as a druggable target opens new avenues for precision interventions in vascular aging and related cardiovascular diseases.
Key Findings
- JPX lncRNA levels rise during endothelial cell senescence and causally promote the SASP inflammatory phenotype.
- JPX forms a trimolecular complex with BRD4 and p65, driving SASP gene transcription in vascular endothelial cells.
- Knockdown of JPX reduces senescence markers; overexpression worsens them in HUVECs.
- Dasatinib + quercetin disrupts the JPX-BRD4-p65 complex, reducing endothelial senescence in vitro and in vivo.
- JPX-BRD4-p65 axis identified as a novel therapeutic target for vascular aging diseases.
Methodology
The study used LPS-induced senescence in human umbilical vein endothelial cells (HUVECs) as its primary cell model, with JPX gain- and loss-of-function assays. Mechanistic studies employed co-immunoprecipitation and transcriptional assays to characterize the JPX-BRD4-p65 complex, complemented by in vivo validation.
Study Limitations
The LPS-induced senescence model is an acute inflammatory surrogate and may not replicate the gradual, multifactorial nature of age-related vascular senescence. Human vascular tissue from aged donors was not directly studied, limiting immediate clinical translation. The specific in vivo model details are not disclosed in the abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: